- Home
- SEGG vs NRSN Comparison
SEGG vs NRSN Comparison
Compare SEGG & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEGG | NRSN |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 14.2M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SEGG | NRSN |
|---|---|---|
| Price | $2.91 | $0.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $20.00 | $8.50 |
| AVG Volume (30 Days) | 40.5K | ★ 472.2K |
| Earning Date | 05-20-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,779,057.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $0.25 |
| 52 Week High | $5.80 | $1.30 |
Technical Indicators
Market Signals| Indicator | SEGG | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 59.93 | 39.82 |
| Support Level | $2.34 | $0.25 |
| Resistance Level | $3.12 | $0.74 |
| Average True Range (ATR) | 0.29 | 0.06 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 43.01 | 16.86 |
Price Performance
Historical ComparisonAbout SEGG Lottery.com Inc.
Sports Entertainment Gaming Global Corp is operated as a single-reporting unit focused on its lottery and gaming platform, and its organizational structure, internal reporting systems, and resource allocation processes were aligned accordingly.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.